How do ai startups make money?

AI startups make money by monetizing one of three things

Most AI startups (including medtech) ultimately get paid for (1) time saved, (2) better decisions, or (3) reduced risk. The “AI” is rarely the product customers buy; they buy a measurable improvement in workflow, quality, or cost.

In healthcare, your revenue model is constrained by three realities:

• Regulatory status: Is it clinical decision support (CDS) vs Software as a Medical Device (SaMD)? If it’s SaMD, your FDA pathway (often 510(k), sometimes De Novo, rarely PMA) affects timeline and what you can claim.
• Who pays vs who uses: Clinicians may love it, but the buyer might be the hospital, a radiology group, a payer, or a device OEM.
• Reimbursement: If you want clinicians to get paid for using it, you’ll need a reimbursement strategy (e.g., CPT codes) or you must sell to an entity that captures the savings.

Below are the main ways AI startups make money, with medtech-specific examples and the tradeoffs founders usually miss.

1) SaaS subscriptions (per site, per seat, or per modality)

SaaS (software-as-a-service) means recurring subscription revenue. In medtech AI, this often looks like a hospital or practice paying annually for access to your software.

Common pricing shapes

• Per site / per facility: One price for a hospital, imaging center, or clinic location.
• Per seat: Price per clinician user (often hard in hospitals due to shared accounts and turnover).
• Per modality / department: E.g., radiology vs cardiology vs ED workflows.

Why it works: Predictable revenue, easier forecasting, and aligns with hospital budgeting cycles.

Why it’s hard in medtech: Hospital procurement can take months, requires security reviews, and often demands integration (EHR/PACS). Also, if your value scales with volume, a flat subscription can underprice you.

Founder tip: Tie the subscription to a clear unit of value (e.g., “ED stroke triage module” or “ICU deterioration monitoring module”) rather than “AI platform.” Platforms are hard to buy.

2) Usage-based pricing (per study, per scan, per alert, per API call)

Usage-based pricing charges based on activity. In imaging AI, it’s often per study or per scan. In monitoring/triage, it might be per patient or per alert.

Why it works: Aligns price with value and makes it easier for a department to start small (“pilot with 1,000 studies”).

Risks: Buyers can fear “runaway costs,” and finance teams may prefer predictable spend. Also, if your algorithm triggers more alerts, you can accidentally penalize yourself unless you price on downstream value.

Practical compromise: Use a minimum annual commitment (baseline subscription) plus usage tiers above that. This is common in enterprise software and reduces procurement friction.

3) Outcome-based or shared-savings contracts (paid when you move a metric)

Outcome-based pricing means you get paid when you achieve a measurable result (e.g., reduced readmissions, shorter length of stay, fewer unnecessary imaging studies). A related structure is shared savings, where you split documented savings with the customer.

Why it’s attractive: It matches how healthcare leaders think: quality metrics, cost reduction, and risk management.

Why it’s difficult: You need clean baseline data, agreement on attribution (what portion of improvement is due to your tool), and a contract structure that legal/procurement will accept. Sales cycles can be longer.

Where it fits best: When your buyer is a payer, an at-risk provider group, or a health system operating under value-based care. If the hospital is fee-for-service and your AI reduces billable volume, you may be “saving money” in a way they don’t want.

4) Reimbursement-driven models (CPT strategy or payer contracts)

Some AI companies build products that can be billed for, directly or indirectly. In the US, that often means a CPT code (a billing code used for reimbursement). Getting paid via reimbursement can be powerful, but it’s not a shortcut.

Two common paths

• Use existing codes: Your tool supports a billable service clinicians already perform (documentation, interpretation, monitoring). You sell software, but the ROI story is “we help you capture revenue you’re missing.”
• Pursue new coding/payment: Longer and uncertain; timelines and outcomes vary. You’ll need clinical evidence, stakeholder support, and a clear definition of the service.

Key nuance: Reimbursement is not the same as “FDA cleared.” FDA status affects what you can claim clinically; reimbursement affects who pays and how much. You often need both a regulatory and a payment plan.

5) Licensing your model or embedding into someone else’s product (OEM/strategic)

Instead of selling to hospitals, you can license your AI to a company that already sells into hospitals: imaging vendors, device manufacturers, EHR/PACS providers, or digital health platforms. They embed your model and pay you via royalties, per-unit fees, or revenue share.

Why it works: Faster distribution if the partner has installed base and procurement relationships. Less burden on your sales team.

Tradeoffs: Lower margins, less control over customer experience, and you can become dependent on one partner’s roadmap. Contracts can be complex (IP rights, liability, performance warranties).

Medtech angle: If your AI is part of a regulated device workflow, your partner may prefer to own the regulatory submission. That can be good (they handle it) or dangerous (you lose leverage). Clarify who owns the FDA file, post-market obligations, and change control.

6) Services + software (the “wedge” model)

Many early-stage AI startups start with services to fund development and learn the workflow: data labeling, model customization, integration, clinical validation support, or analytics consulting. Then they “productize” into recurring software revenue.

Why it’s common: Hospitals have messy data and unique workflows. Services help you get to a working deployment and generate early revenue.

Risk: Services don’t scale like software. If every deal requires heavy customization, you’ll struggle to reach venture-scale margins.

Rule of thumb: Use services to discover repeatable patterns, then turn those into a standard implementation package and product features.

How to choose the right model in medtech (a simple decision framework)

Use these questions to narrow your model:

1. Who is the economic buyer? (department head, CIO, CMIO, payer, OEM). If you can’t name the buyer, you don’t have a revenue model yet.
2. What budget line does it come from? IT, radiology, quality, population health, device capital budget, or operating expense. This determines procurement behavior.
3. What is the unit of value? Per study, per patient, per avoided adverse event, per hour saved. Your pricing metric should match this.
4. Do you need FDA clearance to sell? If you’re making diagnostic/therapeutic claims, assume you’ll need a regulatory strategy (often 510(k) or De Novo). If you’re “workflow only,” you may still need strong clinical validation and risk management.
5. Can you prove ROI within 90–180 days? Hospitals like pilots, but they hate pilots that don’t convert. Design your deployment to measure 1–2 metrics that finance and clinical leadership care about.

Also plan for IRB approval if you need prospective clinical data at a hospital. IRB timelines vary, and it can become your critical path if you don’t plan early.

What to do next

1. Write a one-page pricing hypothesis: buyer, budget owner, pricing metric (per site vs per study), and a target annual contract value range (even if it’s a guess).
2. Run 10 buyer interviews with the exact role that signs (not just users) and test willingness-to-pay and procurement constraints. Use /interviews.
3. Map your regulatory + evidence path: decide if you’re CDS vs SaMD and outline likely FDA route (510(k), De Novo, or PMA) plus what clinical evidence you’ll need.
4. Build an ROI calculator tied to 1–2 measurable outcomes (time saved, reduced complications, fewer unnecessary studies) and use it in every sales call.
5. Pressure-test your model against competitors (pricing metric, buyer, claims, integrations). Use /Competitor_study.